Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI of Neurometabolic Impairment in ALS and TIA Using Hyperpolarized Pyruvate
2024-516954-24-00Phase 2Authorised
- Sponsor
- Aarhus University
- Start
- Sep 2024
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of Pyruvic acid in amyotrophic lateral sclerosis (ALS) and transient ischaemic attack (TIA) (2 cohorts), sponsored by Aarhus University. Primary endpoint: Cerebral neurometabolic fluxes from hyperpolarized pyruvate. Planned start Sep 2024; status: authorised.
02
Drugs
Pyruvic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)transient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2024-516954-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516954-24-00.